CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Sensors from the FreeStyle Libre 2 and Libre 3 continuous glucose monitoring systems can now be worn during X-rays, CT scans and MRI scans. The news represents a shift in policy from the FDA, one that came after the agency reviewed extensive testing data.

Another MAC has agreed to cover the use of these advanced technologies to evaluate patients for signs of coronary artery disease. 

The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns.

The new AUC document was designed to help care teams know when and how to perform imaging-based cardiovascular evaluations on patients undergoing nonemergent, noncardiac surgery.